BioTOP Berlin-Brandenburg

BioTOP Berlin Brandenburg is the central contact and coordination office for all issues concerning biotechnology in the German capital region.

It is our objective to coordinate all regional activities in biotechnology by networking with all key players and to initiate specific projects in order to turn Berlin-Brandenburg into a globally leading life science cluster.

The services provided by BioTOP include:
·  Technology transfer science - industry
·  Initiation and support of networks
·  Support for technology-oriented start-ups
·  Funding support for innovative projects
·  Providing information on biotechnology
·  Building and coordination of scientific and interdisciplinary networks
·  Establishing contacts between experts from all disciplines
·  Design and organization of events
·  Public relations work for the biotech region Berlin-Brandenburg

For more information, including a database with comprehensive profiles of all companies and scientific work groups, please visit our website at www.biotop.de.

Address:
BioTOP Berlin-Brandenburg
Fasanenstr. 85
10623 Berlin - Germany
Contact:
Dr. Kai Bindseil
Phone +49 30 318 622 11
Fax     + 49 30 318 622 22
bindseil@biotop.de

www.biotop.de

back to top

BioTop

Business Wire

Business Wire is a trusted partner to hundreds of Health, Medical, Biotech and Pharmaceutical companies and organizations throughout the world, delivering more corporate news releases from more sources to more destinations than any other service.

Business Wire's news wire circuits enable you to target your news to select audiences based on your geographic and industry market needs. In fact, Business Wire's delivery network is composed of some 60 news agencies, financial and information providers and web-based news services around the globe. From delivery to audiences in a single city to comprehensive worldwide coverage including translations, Business Wire offers you an easy, one-stop solution.

For additional information email tradeshow@businesswire.com or visit www.businesswire.com

Back to top

Business Wire

Citigate Dewe Rogerson

Citigate Dewe Rogerson is the leading international consultancy specialising exclusively in financial and corporate communications across the UK, Europe, North America and Asia.

Citigate has a dedicated Pharma & Biotech team with more than 60 years combined experience in the sector and a unique mix of skills: corporate and financial PR and investor relations, finance, journalism and academic science. The team provides sector expertise and forms an integrated part of Citigate Dewe Rogerson, benefiting from the company’s overall strength and from the cross-fertilisation of ideas across sectors.  

The Citigate Pharma & Biotech team has an established track record in working with biotechnology companies at all stages in development. As well as core skills in financial calendar work, transactions support, financial PR and media relations, the team has extensive experience in branding, design and new media consultancy. Recent clients include global top-five biotechs, listed companies in the UK and Europe, and numerous emerging businesses in the UK, France, Germany, the Netherlands, and Scandinavia.

Citigate’s Pharma & Biotech team has been involved in major corporate transactions such as IPOs, other public and private fundraisings, and M&As.  We have advised on a number of IPO transactions across Europe including; METabolic EXplorer (Euronext Paris - €52 million), Algeta (Oslo Stock Exchange - €30 million), Santhera Pharmaceuticals (SWX – CH88.5 million), ThromboGenics (Euronext Brussels - €35 million), Hutchison China MediTech (AIM - £40 million), Zentiva (LSE and PSE – US $211 million), Arpida (SWX - €63 million), Inion (LSE - £35 million), TopoTarget (CSE - €30 million), BioFusion (AIM - £8.2 million) and ExonHit (Alternext - 7.3 million).

www.citigatedr.co.uk

back to top

Citigate Dewe Rogerson

College Hill

College Hill Life Sciences provides a full service communications consultancy focused on science-based sectors. Within the life science field we have established a leadership position by working in partnership with our clients to deliver high quality communications that build corporate value and promote leading edge products, technologies and services).

www.collegehill.com/lifesciences

back to top

College Hill

Going Public Media AG

Founded in1998 GoingPublic Media AG is today one of the leading publishers of magazines on technology trends, corporate finance and capital markets. 70-80 magazines, newsletters and books are being edited, printed and distributed each year. In addition to the monthly issued “GoingPublic Magazin” and its well known yearly special editions like “Corporate Finance & Private Equity Guide” or “Biotechnology” which are largely meant as reference books, the company publishes the likewise monthly “VentureCapital Magazin” (www.venturecapital.de). It stands as a hub for the private equity and venture capital industry in German speaking Europe and addresses investors and entrepreneurs who focus on trends in technology, corporate financing and venture capital/private equity. Special topics are additionally treated in supplements and special editions (“Tech-Guide”, “Start-up” a.o.). Since 2003, GoingPublic Media AG addresses retail investors via its subsidiary Smart Investor Media GmbH and the monthly issued magazine Smart Investor. The quarterly published “HV Magazin” focuses on organizational, technical und legal trends concerning the annual shareholder meeting and is directed to the responsibles of listed companies (CFOs, investor relations managers etc.). New in 2007 is “Unternehmeredition”, which focuses quarterly on Small and Medium-sized Business Entrepreneurs. Furthermore GoingPublic Media operates the corporate publishing division GoingPublic Services. About 10 magazines and newsletters are annually distributed on behalf of well-known venture capital companies and financial institutions. Since November 2006 GoingPublic Media is listed in the open market of Frankfurt stock exchange. The complete prospectus can be found at www.goingpublic.de/ir.

All publications are published in German.

Contact:
GoingPublic Media AG
Bahnhofstr. 26
82515 Wolfratshausen
Germany

Markus Rieger, CEO
Tel.: +49 (0) 8171/4196-50; rieger@goingpublic.de

Websites: www.goingpublic.de, www.vc-magazin.de, www.hv-magazin.de, www.smartinvestor.de, www.unternehmeredition.de

back to top

Going Public

Medical Device Developments

Medical Device Developments serves a growing international device industry now valued at over $160bn.

Each edition boasts a line-up of leading industry professionals covering the major themes and addressing the key issues currently shaping the market. 
By combining expert opinion with case studies and technical papers relating to every sector within the device industry, Medical Device Developments is designed to provide senior personnel within the major medical OEMs with the overview they need to lead the development of their organisation.

The publication is supported online by medicaldevice-network.com, a site used by the industry as a daily reference point covering current opinion and the latest developments as well providing a platform from which manufacturers can source suppliers and establish long-term supply partnerships.

For more details please visit medicaldevice-network.com

Back to top

Medical Device Developments

Pharmalicensing

Pharmalicensing is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting in- and out-licensing activities, Pharmalicensing provides partnering services, business development reports, industry news and a jobs source for candidates and employers.

Pharmalicensing is used by over 90,000 users per month and is a division of UTEK Corporation. Visit www.pharmalicensing.com

Back to top

Pharma Licensing
SwissBiotech – One Nation – One Biotech Cluster

SwissBiotech unites the various biotech regions of Switzerland: in a targeted manner, the alliance raises Switzerland's profile as an economic centre abroad and positions its biotech regions as innovative and entrepreneurial focal points of research and production.

Its mission; to spread the message of Switzerland as one of the top biotech locations in the world. This will be achieved by presenting a comprehensive picture of biotechnology including research, education, economics, finance and industry.

The base for success in Biotechnology is the critical mass of research institutes and rapid Tec transfer. The vicinity to industry and well-trained workforce is another key-driver for success in economy. Recently regions in Switzerland opened a series of ‘Biotech-Parks’ thus enabling to offer ideal geographical placement of companies seeking short distances and increased know-how transfer between universities and industry. State-of-the-art technological infrastructures, productive international human resources and a traditional well publicized quality of life.

Six founding members:
Four leading Biotech regions of Switzerland (Bio Alps, Bio Polo Ticino, BioValley Basel and Greater Zurich Area) have combined efforts to streamline interests of the national Biotech sector. Selective access to the private equity business is one of their today’s services when setting up a business in Switzerland. The SWX Swiss Exchange holds a leading position in terms of life-science listings and offers companies from that industry- be they located in Switzerland or abroad – access to an internationally recognized financial marketplace. The initiative has been complimented early on by the national association of the industry, Swiss Biotech Association.

Swiss online life-science database available
At www.swisslifesciences.com the visitor will find a comprehensive compilation of the Biotech sector of Switzerland. In addition to biotech companies, the database includes medtech and life-science companies and organizations, as well as investors specializing in these fields. All data is categorized according to sector and sub sector so that systematic searches can be carried out.

The national portal www.swissbiotech.org holds unique information relating to all questions on Biotechnology in Switzerland.

SwissBiotech
Lukas Huber
Tel. +41 44 254 59 08
Lukas.huber@greaterzuricharea.ch

www.swissbiotech.com

back to top

Swiss Biotech Association